Kintara Therapeutics Announces Fiscal Year 2021 Financial Results and Provides Corporate Update Sep 29, 2021
Kintara Announces $15.0 million Offering of Common Stock and Warrants Priced at a Premium to Market Sep 24, 2021
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients Sep 22, 2021
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma Aug 17, 2021
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021 Aug 12, 2021
Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021 Aug 4, 2021
